Silence Therapeutics said its siRNA therapy divesiran succeeded in a Phase 2 study for polycythemia vera (PV) by meeting its primary endpoint. The company plans to advance the program into Phase 3, positioning divesiran as a potential next-generation option for a rare blood cancer driven by elevated red blood cell production.